JP2023171766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023171766A5 JP2023171766A5 JP2023145605A JP2023145605A JP2023171766A5 JP 2023171766 A5 JP2023171766 A5 JP 2023171766A5 JP 2023145605 A JP2023145605 A JP 2023145605A JP 2023145605 A JP2023145605 A JP 2023145605A JP 2023171766 A5 JP2023171766 A5 JP 2023171766A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- medium
- population
- natural killer
- culturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 142
- 239000002609 medium Substances 0.000 claims description 75
- 210000000130 stem cell Anatomy 0.000 claims description 50
- 238000012258 culturing Methods 0.000 claims description 42
- 210000000822 natural killer cell Anatomy 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 230000001483 mobilizing effect Effects 0.000 claims description 36
- 102000003812 Interleukin-15 Human genes 0.000 claims description 26
- 108090000172 Interleukin-15 Proteins 0.000 claims description 26
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 23
- 239000003055 low molecular weight heparin Substances 0.000 claims description 21
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 21
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 15
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 13
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 12
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 12
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 108010002586 Interleukin-7 Proteins 0.000 claims description 9
- 102000036693 Thrombopoietin Human genes 0.000 claims description 8
- 108010041111 Thrombopoietin Proteins 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000003169 placental effect Effects 0.000 claims description 7
- 108700014844 flt3 ligand Proteins 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 5
- LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 claims description 4
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical group N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 4
- 210000002662 placental hematopoietic stem cell Anatomy 0.000 claims 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 44
- -1 1H-benzimidazolyl Chemical group 0.000 description 33
- 210000004881 tumor cell Anatomy 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 8
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- IEJAIKPHVAPFSS-UHFFFAOYSA-N 9h-pyrimido[4,5-b]indole Chemical group N1C=NC=C2C3=CC=CC=C3N=C21 IEJAIKPHVAPFSS-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 108700012434 CCL3 Proteins 0.000 description 4
- 102000000013 Chemokine CCL3 Human genes 0.000 description 4
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000005955 1H-indazolyl group Chemical group 0.000 description 2
- 102100030751 Eomesodermin homolog Human genes 0.000 description 2
- 101100172469 Escherichia coli (strain K12) envZ gene Proteins 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 2
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 2
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 108091008778 RORγ2 Proteins 0.000 description 2
- 101150077103 TPO gene Proteins 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 101150009274 nhr-1 gene Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242246P | 2015-10-15 | 2015-10-15 | |
| US62/242,246 | 2015-10-15 | ||
| US201562272984P | 2015-12-30 | 2015-12-30 | |
| US62/272,984 | 2015-12-30 | ||
| US201662403571P | 2016-10-03 | 2016-10-03 | |
| US62/403,571 | 2016-10-03 | ||
| PCT/US2016/056988 WO2017066530A1 (en) | 2015-10-15 | 2016-10-14 | Natural killer cells and ilc3 cells and uses thereof |
| JP2018519316A JP2018535666A (ja) | 2015-10-15 | 2016-10-14 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
| JP2021171231A JP2022023148A (ja) | 2015-10-15 | 2021-10-19 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021171231A Division JP2022023148A (ja) | 2015-10-15 | 2021-10-19 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023171766A JP2023171766A (ja) | 2023-12-05 |
| JP2023171766A5 true JP2023171766A5 (https=) | 2024-04-04 |
Family
ID=58517926
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519316A Pending JP2018535666A (ja) | 2015-10-15 | 2016-10-14 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
| JP2021171231A Pending JP2022023148A (ja) | 2015-10-15 | 2021-10-19 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
| JP2023145605A Pending JP2023171766A (ja) | 2015-10-15 | 2023-09-07 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519316A Pending JP2018535666A (ja) | 2015-10-15 | 2016-10-14 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
| JP2021171231A Pending JP2022023148A (ja) | 2015-10-15 | 2021-10-19 | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20180346877A1 (https=) |
| EP (1) | EP3362075B1 (https=) |
| JP (3) | JP2018535666A (https=) |
| KR (1) | KR20180059555A (https=) |
| CN (1) | CN109310710A (https=) |
| AU (1) | AU2016340005B2 (https=) |
| BR (1) | BR112018007538A2 (https=) |
| CA (1) | CA3002066A1 (https=) |
| CO (1) | CO2018004937A2 (https=) |
| EA (1) | EA201890960A1 (https=) |
| IL (1) | IL258666B2 (https=) |
| MX (1) | MX2018004600A (https=) |
| MY (1) | MY201637A (https=) |
| NZ (1) | NZ741612A (https=) |
| SG (2) | SG10201912576PA (https=) |
| TW (1) | TW201732037A (https=) |
| WO (1) | WO2017066530A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3077325A1 (en) * | 2017-09-28 | 2019-04-04 | Celularity Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
| US12011460B2 (en) | 2018-02-20 | 2024-06-18 | Universite De Montreal | Expansion of NK and DC cells in vivo mediating immune response |
| CN108486054B (zh) * | 2018-04-12 | 2022-04-19 | 平安爱普德（北京）生物技术有限公司 | 一种体外扩增i型天然细胞毒性淋巴细胞ilc1/nk的方法 |
| CN113454207A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞 |
| WO2020231200A1 (ko) * | 2019-05-15 | 2020-11-19 | 오정훈 | 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트 |
| WO2020252464A1 (en) * | 2019-06-14 | 2020-12-17 | Celularity Inc. | Populations of natural killer cells for treating cancers |
| CA3145510A1 (en) * | 2019-07-29 | 2021-02-04 | Deverra Therapeutics Inc. | Nk cell composition and preparations for immunotherapy and methods for their production |
| AU2020409437A1 (en) * | 2019-12-18 | 2022-07-14 | Universite De Montreal | Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds |
| WO2021155312A1 (en) * | 2020-01-29 | 2021-08-05 | Celularity Inc. | Placental derived natural killer cells for treatment of coronavirus infections |
| US12195759B2 (en) | 2020-02-21 | 2025-01-14 | FullHope Biomedical Co., Ltd. | Modified natural killer cells, pharmaceutical composition, manufacturing method thereof, and method of using the same |
| JP7793284B2 (ja) * | 2020-03-02 | 2026-01-05 | 株式会社ガイアバイオメディシン | 高活性ｎｋ細胞の処理方法 |
| KR20220048775A (ko) * | 2020-10-13 | 2022-04-20 | 주식회사 노보셀바이오 | Nk 세포를 유효성분으로 포함하는 항바이러스 조성물 |
| CN112285083B (zh) * | 2020-10-28 | 2022-01-07 | 上海睿钰生物科技有限公司 | 一种细胞杀伤效力的评价方法 |
| CN112251406B (zh) * | 2020-10-30 | 2023-06-09 | 曹峰林 | 一种nk细胞活化阶段的外泌体分选方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| KR20240063899A (ko) * | 2021-09-08 | 2024-05-10 | 가부시키가이샤 가이아바이오메디신 | 세포의 처리 방법 |
| WO2025028596A1 (ja) * | 2023-08-02 | 2025-02-06 | 株式会社ヘリオス | ナチュラルキラー細胞の製造方法 |
| CN117511867B (zh) * | 2023-10-07 | 2024-08-06 | 深圳泽医细胞治疗集团有限公司 | 一种靶向肺部且高表达nkg2d的nk细胞的培养试剂盒及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US9862928B2 (en) * | 2010-12-03 | 2018-01-09 | Regents Of The University Of Minnesota | Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells |
| ES2856825T3 (es) * | 2011-03-18 | 2021-09-28 | Glycostem Therapeutics B V | Generación de células NK y progenitores de células NK |
| PT2807165T (pt) * | 2012-01-27 | 2019-07-12 | Univ Montreal | Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas |
| DK2812011T3 (da) * | 2012-02-08 | 2020-02-24 | Glycostem Therapeutics B V | Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler |
| CN114134113A (zh) * | 2012-08-13 | 2022-03-04 | 人类起源公司 | 自然杀伤细胞及其用途 |
| US9074186B2 (en) * | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
| CA2923314A1 (en) * | 2013-09-05 | 2015-03-12 | Sanford-Burnham Medical Research Institute | Modulation of .gamma..delta.t cells |
| EP3057986B1 (en) * | 2013-10-17 | 2017-12-27 | National University of Singapore | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
| NZ733213A (en) * | 2014-12-31 | 2022-10-28 | Celularity Inc | Natural killer cells and uses thereof |
| EP3350316B1 (en) | 2015-09-15 | 2024-05-08 | Stichting Radboud universitair medisch centrum | IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST |
| CN109843304A (zh) * | 2016-05-07 | 2019-06-04 | 细胞结构公司 | 使用自然杀伤细胞治疗急性髓性白血病和多发性骨髓瘤的方法 |
-
2016
- 2016-10-14 MY MYPI2018701476A patent/MY201637A/en unknown
- 2016-10-14 TW TW105133346A patent/TW201732037A/zh unknown
- 2016-10-14 AU AU2016340005A patent/AU2016340005B2/en not_active Ceased
- 2016-10-14 CA CA3002066A patent/CA3002066A1/en active Pending
- 2016-10-14 BR BR112018007538A patent/BR112018007538A2/pt not_active Application Discontinuation
- 2016-10-14 NZ NZ741612A patent/NZ741612A/en not_active IP Right Cessation
- 2016-10-14 WO PCT/US2016/056988 patent/WO2017066530A1/en not_active Ceased
- 2016-10-14 SG SG10201912576PA patent/SG10201912576PA/en unknown
- 2016-10-14 SG SG11201803117YA patent/SG11201803117YA/en unknown
- 2016-10-14 CN CN201680074724.8A patent/CN109310710A/zh active Pending
- 2016-10-14 US US15/768,505 patent/US20180346877A1/en not_active Abandoned
- 2016-10-14 KR KR1020187013666A patent/KR20180059555A/ko not_active Ceased
- 2016-10-14 EA EA201890960A patent/EA201890960A1/ru unknown
- 2016-10-14 IL IL258666A patent/IL258666B2/en unknown
- 2016-10-14 JP JP2018519316A patent/JP2018535666A/ja active Pending
- 2016-10-14 EP EP16856249.4A patent/EP3362075B1/en active Active
- 2016-10-14 MX MX2018004600A patent/MX2018004600A/es unknown
-
2018
- 2018-05-09 CO CONC2018/0004937A patent/CO2018004937A2/es unknown
-
2021
- 2021-10-19 JP JP2021171231A patent/JP2022023148A/ja active Pending
-
2022
- 2022-11-16 US US18/056,088 patent/US20230142803A1/en active Pending
-
2023
- 2023-09-07 JP JP2023145605A patent/JP2023171766A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023171766A5 (https=) | ||
| JP2018502115A5 (https=) | ||
| JP7653759B2 (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP2022023148A (ja) | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 | |
| US9925220B2 (en) | Method of expanding double negative T cells | |
| JP2015504902A5 (https=) | ||
| RU2015108761A (ru) | Природные клетки-киллеры и их применение | |
| CN107405364A (zh) | 自然杀伤细胞及其用途 | |
| JP2008517948A5 (https=) | ||
| Huang et al. | Sca-1+ cardiac stem cells mediate acute cardioprotection via paracrine factor SDF-1 following myocardial ischemia/reperfusion | |
| JP2022095927A (ja) | ナチュラルキラー細胞を使用して急性骨髄性白血病および多発性骨髄腫を処置する方法 | |
| US20230338429A1 (en) | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | |
| US20230028680A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
| Du et al. | The different effects of IFN‐β and IFN‐γ on the tumor‐suppressive activity of human amniotic fluid‐derived mesenchymal stem cells | |
| Sayegh et al. | Application of natural killer immunotherapy in blood cancers and solid tumors | |
| Dai et al. | Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice | |
| JPWO2020113182A5 (https=) | ||
| JP7477520B2 (ja) | 幹細胞療法 | |
| WO2021016621A1 (en) | Populations of natural killer cells comprising a cd38 chimeric antigen receptor | |
| Zhang et al. | Deficiency of β common receptor moderately attenuates the progression of myeloproliferative neoplasm in NrasG12D/+ mice | |
| JPWO2019161494A5 (https=) | ||
| Rejeski et al. | Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxicity | |
| Cabré Margalef | Beyond CAR-T: Advancements in CAR-NK and CAR-NKT Therapies for Cancer Treatment | |
| Schmidt et al. | From bench to bedside: Exploiting memory NK cell responses to leukemia | |
| Lee | Comparative Analysis of Cytokine Levels in Multiple Myeloma Patients: Implications for Natural Killer Cells and Therapeutic Monoclonal Antibodies |